Five-year overall survival of early- and late-onset colorectal cancer in Medellín, Colombia: a comparative study
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Early-onset colorectal cancer (CRC) patients demonstrate significantly better 5-year survival rates than late-onset CRC patients. Advanced stage and higher tumor grade predict poorer outcomes in all CRC cases.
Area Of Science
- Oncology
- Gastroenterology
- Epidemiology
Background
- Early-onset colorectal cancer (EOCRC) (<50 years) presents distinct features from late-onset colorectal cancer (LOCRC) (≥50 years).
- Existing evidence on survival outcomes between EOCRC and LOCRC is conflicting.
Purpose Of The Study
- To analyze and compare the 5-year overall survival (OS) rates between EOCRC and LOCRC.
Main Methods
- A retrospective cohort study included 1022 CRC patients diagnosed between 2018-2022 in Medellín, Colombia.
- Data on clinicopathological features and survival were collected from medical records and a government database.
- Kaplan-Meier method and Cox regression models were used to calculate 5-year OS rates and identify prognostic factors.
Main Results
- EOCRC patients (13.5%) exhibited higher 5-year OS rates (54%) compared to LOCRC patients (32%).
- EOCRC was associated with a 37% lower risk of death (HR: 0.633, p=0.002) in univariable analysis.
- Multivariable analysis confirmed EOCRC as a factor for higher OS (HR: 0.482, p=0.000), while advanced stage and higher tumor grade predicted worse OS.
Conclusions
- EOCRC is linked to significantly better 5-year OS rates and prognosis than LOCRC.
- Advanced stage and high tumor grade are independent predictors of reduced OS in all colorectal cancer patients.
- Findings underscore the need for age-specific risk stratification and tailored therapies in CRC management.
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
Related Concept Videos
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and...